The study applies the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire in older patients hospitalized in an acute care geriatric unit and aims to determine its performance indicators to screen for sarcopenia according to the revised European Consensus on definition and diagnosis (EWGSOP2) within this population
Sarcopenia is an age-related disease associated with health adverse outcomes, i.e. higher risk of mobility limitation, falls, fractures, mortality, and lower quality of life. The European Working Group on Sarcopenia has recently revisited one of the widely used most acknowledged definitions and launched the revised European consensus on definition and diagnosis (EWGSOP2) (4). Applying the EWGSOP2 is a three-tier process: first, screening by the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire; second, diagnosis by low muscle strength, and low muscle mass; third, severity grading by low muscle function. The EWGSOP2 recommends the assessment of sarcopenia in every population, both in community-dwelling and acute care older patients. However, the evidence about the performance indicators of the SARC-F questionnaire to screen for sarcopenia in acute patients admitted to an acute care unit is really limited.
Study Type
OBSERVATIONAL
Enrollment
105
Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
Brugmann university hospital
Brussels, Belgium
Sensitivity of the SARC-F questionnaire as screening method compared to the gold standard, which is the revised European consensus on definition and diagnosis
Sensitivity, measured as a percentage (%)
Time frame: September 2019-November 2020
Specificity of the SARC-F questionnaire as a screening method, compared to the gold standard which is the revised European Consensus on definition and diagnosis of sarcopenia (EWGSOP2)
Specificity, measured as a percentage (%)
Time frame: September 2019-November 2020
Overall concordance agreement between the SARC-F questionnaire as a screening method and the gold standard method, which is the EWGSOP2
Cohen-kappa coefficient, measured as a percentage (%)
Time frame: September 2019-November 2020
Health adverse outcomes based on the screening and diagnosis of sarcopenia as recommended by the EWGSOP2
Mortality risk
Time frame: 1-year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.